Boehringer Ingelheim
This article was originally published in The Tan Sheet
Executive Summary
German firm is considering divestiture of its Pharmaton Business as part of an ongoing review of its over-the-counter portfolio while weighing "the merits of alternative options," the company announced Sept. 9. The country's top drug maker by sales issued the statement in response to "rumors circulating in the market regarding a potential sale of parts of the Consumer Health Care Business." The segment up for review affects multivitamin and ginseng products sold under the Pharmaton brand, Boehringer said. The option is currently being discussed with financial consultants though no decision has as yet been made, the firm maintains...